Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature

Figures & data

Table 1. Baseline characteristics and procedural details for study participants.

Characteristics	Mean	SD	Range	n
Age (yr)	70.5	10.2	56–90	11
Prostate volume (cc)	45.5	15.1	30–80	11
International Prostate Symptom Score (IPSS)	25.6	5.3	16–33	11
Quality of life	5.0	0.6	4–6	11
Post-void residual volume (ml)	306.3	120.6	120–499	11
QMAX (ml/s)	7.0	2.8	4–14	11
Flexi – small occlusive	N/A	N/A	N/A	5
Flexi – moderate occlusive	N/A	N/A	N/A	5
Flexi – large occlusive	N/A	N/A	N/A	1
Anaesthetic – LA	N/A	N/A	N/A	2
Anaesthetic – GA	N/A	N/A	N/A	8
Anaesthetic – spinal	N/A	N/A	N/A	1
Time in hospital (hours)	10.6	5.8	6–18	11
Operation time (min)	8.5	1.7	6–12	11
Theatre time (min)	18.7	5.3	12–30	11
Number of implants	4.0	0.9	2–6	11
Voiding post-op – yes	N/A	N/A	N/A	9
Voiding post-op – catheter	N/A	N/A	N/A	2
Meds – finasteride	N/A	N/A	N/A	1
Meds- tamsulosin	N/A	N/A	N/A	4
Meds = combination	N/A	N/A	N/A	6

Figure 1. The implant.

Figure 2. The UroLift device.

Table 2. Primary outcomes from UroLift^a.

Characteristics	Baseline mean (SD)	4 Months post-op mean (SD)	Mean difference (SD)	p-Value	n
International Prostate Symptom Score (IPSS)	25.4 (5.5)	16.3 (9.4)	−9.1 (8.0)	.02	10
Quality of life	5.1 (0.6)	3.5 (2.2)	−1.6 (2.4)	.04	10
Post-void residual volume (ml)	300.1 (125.3)	193.8 (86.1)	−106.3 (123.4)	.04	10
QMAX (ml/s)	7.2 (2.8)	8.9 (5.4)	1.7 (3.7)	.39	10

^a One patient excluded from primary outcome analysis due to death from metastatic pancreatic cancer.

p < .05.

Figure 3. 80CC prostate pre- and post-UroLift.

Figure 4. 30–60 cc prostates pre- and post-UroLift.